CTRI/2022/01/039547
Not yet recruiting
未知
An observational study on ekakustha (psoriasis) w s r to deha prakriti
Shri NPA Govt Ayurved college Raipur Chhattisgarh0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shri NPA Govt Ayurved college Raipur Chhattisgarh
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with age group 16 years to 70 years
- •Patient who are willing to participate in the study after giving the consent.
Exclusion Criteria
- •Patient with age group below 16 years to above 70 years
- •patient having any systemic disorder,other skin disease and not willing for study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
To study the effect of vidangadi lepa and tiktaka ghrita in the management of psoriasisCTRI/2024/07/069774Dr Padmaja Rani Panda
Not yet recruiting
Phase 2
Clinical Study Of unani formulation and betamethsone in the treatment of Psoriasis.Health Condition 1: L409- Psoriasis, unspecifiedCTRI/2020/07/026420central counsal for research in unani medicine new delhi
Unknown
Phase 3
A Phase 3 Clinical Study of KHK4827JPRN-jRCT2080222010Kyowa Hakko Kirin Co., Ltd.100
Recruiting
Not Applicable
Evaluation of knowledge, attitude and practice about psoriasis disease and its management among psoriasis patientsHealth Condition 1: L405- Arthropathic psoriasisHealth Condition 2: L401- Generalized pustular psoriasisHealth Condition 3: L404- Guttate psoriasisHealth Condition 4: L408- Other psoriasisHealth Condition 5: L400- Psoriasis vulgarisHealth Condition 6: L409- Psoriasis, unspecifiedHealth Condition 7: L403- Pustulosis palmaris et plantarisCTRI/2021/12/038550Dr Braj Bhushan Kumar
Active, not recruiting
Not Applicable
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CarePsoriasisNCT04780516AbbVie141